Newport's Isoprinosine

Executive Summary

Results from U.S./U.K. study in AIDS-related complex patients with T-helper cell depletion do not support efficacy of the agent and will not be used to seek approval of the drug, Newport reports. The firm is discontinuing the U.S./U.K. study, but says it still may seek approval of the drug for ARC if results from an ongoing Scandanavian or Australian study are more promising. Results from the Scandanavian study are expected in early 1989. The Australian study is a long-term trial in HIV-positive patients without symptoms of immunodeficiency....